RECRUDESCENCE IN ARTESUNATE-TREATED PATIENTS WITH FALCIPARUM MALARIA IS DEPENDENT ON PARASITE BURDEN NOT ON PARASITE FACTORS

WANIDA ITTARAT, AMY L. PICKARD, PANTHIP RATTANASINGANCHAN, POLRAT WILAIRATANA, SORNCHAI LOOAREESUWAN, KATHRYN EMERY, JONATHAN LOW, RACHANEE UDOMSANGPETCH, AND STEVEN R. MESHnick

Departments of Clinical Microscopy, Faculty of Medical Technology, Mahidol University, Bangkok, Thailand; Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill, NC; Hospital for Tropical Disease, Faculty of Tropical Medicine/Mahidol University, Bangkok, Thailand; Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI; Department of Experimental Pathobiology, Faculty of Science, Mahidol University, Bangkok, Thailand

Abstract. Artemisinin derivatives are first-line antimalarial drugs in Thailand. No firm evidence of clinically relevant artemisinin resistance exists. When used as monotherapy, artesunate has been associated with a high treatment failure (recrudescence) rate, which could be due to low-level artemisinin resistance. To understand the causes of recrudescence, we retrospectively studied a cohort of 104 malaria patients treated with artesunate monotherapy, 32 of whom recurred. There was no difference in in vitro artesunate sensitivities between 6 nonrecrudescent isolates and 16 paired admission and recrudescent isolates. Paired admission and recrudescent isolates from 10 patients were genotyped; only 3 had pfmdr1 mutations. Patients with admission parasitemias >10,000 per μl had a 9-fold higher likelihood of recrudescence (adjusted odds ratio) compared with patients with lower parasitemias. This study suggests (1) recrudescence after treatment with artesunate is not the result of inherent parasite resistance, and (2) admission parasitemia may be useful in choosing therapeutic options.

MATERIALS AND METHODS

This study was approved by the Ethics Committee of Mahidol University. Unless specified, all chemicals used in the present study were purchased from Sigma (St. Louis, MO).

Patient recruitment, treatment, and evaluation. Of 320 patients with falciparum malaria admitted during the period April 1998–March 1999 to the Bangkok Hospital for Tropical Diseases, Thailand, 150 patients were treated with artesunate tablets (600 mg total dose in 3 days; Guilin No. 1 Factory, Guangxi, China, registered for use in Thailand). Blood was collected routinely from all malaria patients. Inclusion criteria were as follows: had a case of acute uncomplicated falciparum malaria, were >18 years old, had no treatment with artemisinin derivatives during the previous 2 weeks, and gave informed consent. There were 104 patients who met the inclusion criteria for this study. Patients remained in the hospital for 28 days and had daily blood smears. Blood samples were taken before treatment on the day of admission and at the time of recrudescence and were stored in liquid nitrogen. Routine blood chemistry and hematologic parameters were determined automatically using a Boehringer Mannheim Hitachi 917 (Boehringer Mannheim, Indianapolis, IN) and Gen S (Coulter, Hialeah, FL).

The freezing solution for cryopreservation of parasites was prepared by first filtering a solution of either sorbitol or glyc erol (4.2%) in 0.9% sodium chloride, through a 0.45-μm filter (New Bedford, MA). This solution was mixed with 99% glycerol to make a solution containing 3% sorbitol or glycerol, 0.65% sodium chloride, and 28% glyc erol. Before cryopreservation, ring-stage patient blood samples were centrifuged at 400×g for 7 minutes at 4°C. The plasma was discarded, and the cell pellet was mixed with an equal volume of freezing solution. The mixture was divided into 0.5-ml aliquots, frozen, and stored in liquid nitrogen.

Parasite density was obtained from thin blood smears: 1,000 erythrocytes were examined, and the number of these infected with plasmodia yielded the percent parasitemia. Para-
sitemias were calculated as parasites per microliter of blood (multiplying percent parasitemia and red blood cell [RBC] counts).

**Parasite drug sensitivity tests.** Blood samples were thawed, and the *in vitro* culture of the blood stage malaria parasite was performed by candle jar method as described previously using human AB serum. Aliquots were removed and thawed under water at room temperature. An equal volume of 3.5% sodium chloride was added, and the mixture was centrifuged at 400g for 7 minutes at 4°C. The pellet was washed 3 times with stock RPMI 1640 medium and resuspended in RPMI. Parasites were cultured in a candle jar at 37°C until parasitemia reached 0.4% to 0.6% and were used for drug sensitivity assays. Individual isolates were not cultured for equal duration because culture time depended on starting parasitemia level; generally, no cultures were >1 month. Sensitivities to dihydroartemisinin were determined by the microdilution method using tritiated hypoxanthine incorporation. A 2-fold serial dilution of dihydroartemisinin was prepared in a 96-well plate to which a parasitized RBC suspension, mostly at the ring stage, was added. The plate was incubated at 37°C for 24 hours in a candle jar. Tritiated hypoxanthine (American, Arlington Heights, IL) was added, after which the plate was incubated for another 18–20 hours. The infected cell suspension was harvested (Nunc Cell Harvester 8; Nalge Nunc International, Rochester, NY) and hypoxanthine incorporation was determined by a scintillation counter (Tricarb 2700 TR; Packard Company).

**Hemoglobin typing and measurement of glucose-6-phosphate dehydrogenase.** Hemoglobin type was analyzed by cellulose acetate electrophoresis according to the method described by the manufacturer (Helena Laboratories, Beaumont, TX). Hemoglobins are separated at a pH of 8.6 on a cellulose acetate electrophoresis according to the method described by the manufacturer (Helena Laboratories, Beaumont, TX). Under these conditions, hemoglobin A2 was eluted while normal, and other abnormal hemoglobins were oxidized to 6-phosphogluconate, while TPN was reduced with saponin, and oxidized glutathione (GSSG) in potassium phosphate buffer was added. In the presence of G6PD, the substrate, G-6-P, was incubated for another 18–20 hours. The infected cell suspension was harvested (Nunc Cell Harvester 8; Nalge Nunc International, Rochester, NY) and hypoxanthine incorporation was determined by a scintillation counter (Tricarb 2700 TR; Packard Company).

**Characteristics of recrudescent and nonrecrudescent parasite isolates.** Of all the available blood samples, *in vitro* parasite cultures were obtained successfully from 6 nonrecrudescent patients and 16 recrudescent patients (on admission and during the episode of recrudescence) (Figure 1). Because artemisinate is rapidly converted to dihydroartemisinin in *vivo*, 50% inhibitory concentrations (IC50) for dihydroartemisinin were determined for each parasite isolate. A Wilcoxon signed rank test (for recrudescent versus nonrecrudescent patients) and a paired *t*-test (for admission versus recrudescent isolates) were used to evaluate differences in IC50. There were no significant differences in IC50 for parasites from recrudescent patients on admission (0.57 ± 0.44 ng/ml; range, 0.17–1.56 ng/ml) or recrudescence (0.615 ± 0.534 ng/ml; range, 0.12–1.75) or from nonrecrudescent patients (0.45 ± 0.22 ng/ml; range, 0.2–0.86 ng/ml).

Because all samples were frozen in liquid nitrogen before IC50 determination, the effects of freezing and thawing on IC50 were tested using the laboratory strain (K1). K1 was frozen and thawed under similar conditions (n = 5). The IC50 was 0.38 ± 0.09 ng/ml before and 0.30 ± 0.07 ng/ml after freeze-thawing. There was no statistically significant difference using a paired *t*-test (P = 0.87), indicating that freezing, thawing, and reculturing did not affect the determination of IC50.

In previous reports, *pfmdr1* mutations have been associated with altered *in vitro* sensitivity to artemisinins. Sequence polymorphisms in *pfmdr1* that may decrease sensitivity have been reported at several codon positions: N86Y, Y184F, S1034C, N1042D, and D1246Y. For genotyping experiments, new cultures had to be established from cryopreserved stabilates. Cultures were obtained successfully from 10
recrudescent patients (from isolates obtained on admission and during their recrudescent episodes). We PCR amplified and sequenced the \textit{pfmdr1} genes from the admission and recrudescent cultures from these 10 patients. Initial and recrudescent cultures from 7 of 10 patients had wild-type \textit{pfmdr1} genotypes. Isolates from only 3 patients had mutations. In 2 of these 3 patients, isolates showed the same mutations before and after treatment (one had the N1042D mutation and the other was Y184F). In 1 of the 3 patients, the pretreatment isolate had a Y184F mutation that was not found in the post-treatment strain, suggesting that the original infection may have been polyclonal and that the nonmutant strain was responsible for the recrudescence.

**Characteristics of recrudescent and nonrecrudescent patients.** The characteristics of the 32 recrudescent patients and 72 nonrecrudescent patients are shown in Table 1. The ages of patients with and without recrudescence were similar (25.9 ± 6.8 years and 24.9 ± 8.0 years). Both groups were predominantly male (69% of recrudescent patients and 63% of nonrecrudescent patients). None of the patients were homozygous for thalassemia. Of 103 patients, 18 (17.3%) were heterozygous for hemoglobin E (Hb EA), a type of \( \beta \)-thalassemia, and of 104 patients, 9 (8.7%) had G6PD deficiency. No other abnormal hemoglobin bands were detected. There were no significant differences between the 2 groups in admission blood chemistries, mean corpuscular volume, mean corpuscular hemoglobin concentration, or platelet counts or in the percentage of patients with G6PD deficiencies or thalassemic trait.

There were several significant differences between patients who had recrudescence and patients who did not. First, the recrudescent patients had higher percent parasitemias on admission (2.65% versus 0.45% in nonrecrudescent patients). Second, recrudescent patients had significantly higher RBC counts, hemoglobin levels, and hematocrits (Table 1). Together, these data suggest that patients with higher parasite burdens were more likely to have recrudescence. When the number of parasites per microliter of blood was calculated, the difference was highly significant \((P = 0.0035)\). The only other variable that was significantly different between recrudescent and nonrecrudescent patients was the white blood cell (WBC) count; recrudescent patients had significantly higher WBC counts than nonrecrudescent patients (6.6 versus 5.7). The odds ratio (OR) for recrudescence for patients having WBC counts >5.85 (the median) was 3.08 (95% confidence interval [CI], 1.27–7.44).

Logistic regression was done to confirm the association between recrudescence and factors found to be significant in univariate analyses, including RBC count, hematocrit, hemoglobin level, and percent parasitemia and parasitemia (number of parasites/\( \mu \)l) (Table 1). The level of parasitemia was represented by a dichotomous variable for high/low level of parasitemia, with 10,000 parasites/\( \mu \)l as the cut-point.\(^\text{15}\) (Similar results were found when the median, 12,150, was used as the cut-point.) Many of these factors are either closely related (RBC count, hemoglobin, and hematocrit) or indirectly related (i.e., RBC count × percent parasitemia = parasitemia). The strongest univariate association was with parasitemia,
### Table 1
Characteristics of recrudescent and nonrecrudescent patients

<table>
<thead>
<tr>
<th></th>
<th>Recrudescent (n=32)</th>
<th>Nonrecrudescent (n=72)</th>
<th>P value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of infected patient (yr)</td>
<td>25.9 (13–41)</td>
<td>26.9 (14–49)</td>
<td>NS</td>
</tr>
<tr>
<td>Sex of infected patients (M:F)</td>
<td>22:10</td>
<td>45:27</td>
<td>NS</td>
</tr>
<tr>
<td>Percent parasitemia on admission</td>
<td>2.65 (0.02–20.20)</td>
<td>0.45 (&lt;0.01–0.40)</td>
<td>0.0106</td>
</tr>
<tr>
<td>Parasitemia (per μL)</td>
<td>116,000 (590–776,000)</td>
<td>19,000 (30–174,000)</td>
<td>0.0035</td>
</tr>
<tr>
<td>Parasitemia, &gt;10,000 per μL (no. [%])</td>
<td>28 (87.5)</td>
<td>30 (41.7)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Samples with G6PD deficiency (%)</td>
<td>2 (6.3)</td>
<td>7 (9.3)</td>
<td>NS†</td>
</tr>
<tr>
<td>Hb EA–containing samples (%)</td>
<td>3 (9.4)</td>
<td>16 (21.1)</td>
<td>NS†</td>
</tr>
<tr>
<td>AST (IU/L)</td>
<td>71.3 (20–315)</td>
<td>53.0 (15–266)</td>
<td>NS</td>
</tr>
<tr>
<td>ALT (IU/L)</td>
<td>57.9 (5–266)</td>
<td>53.7 (8–211)</td>
<td>NS</td>
</tr>
<tr>
<td>BUN (mg/dL)</td>
<td>19.25 (3.50–91.20)</td>
<td>13.6 (0.55–62.00)</td>
<td>NS</td>
</tr>
<tr>
<td>Alkaline phosphatase (IU/L)</td>
<td>101.5 (53.0–228.8)</td>
<td>109.8 (34.1–279.6)</td>
<td>NS</td>
</tr>
<tr>
<td>RBC (1 million per μL)</td>
<td>4.6 (2.6–6.5)</td>
<td>4.2 (2.2–6.2)</td>
<td>0.030</td>
</tr>
<tr>
<td>Hemoglobin (%)</td>
<td>12.3 (7.8–15.7)</td>
<td>11.1 (6.4–16.8)</td>
<td>0.022</td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td>37 (22–48)</td>
<td>34 (19–50)</td>
<td>0.020</td>
</tr>
<tr>
<td>MCV (fl)</td>
<td>82 (64–96)</td>
<td>82 (57–98)</td>
<td>NS</td>
</tr>
<tr>
<td>MCHC (%)</td>
<td>32.9 (31–35)</td>
<td>33 (30–35)</td>
<td>NS</td>
</tr>
<tr>
<td>WBC (1,000 per μL)</td>
<td>6.6 (1.9–13.2)</td>
<td>5.7 (2.1–11.2)</td>
<td>0.053</td>
</tr>
<tr>
<td>Platelets (1,000 per μL)</td>
<td>90 (11–243)</td>
<td>109 (11–358)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Note: Arithmetic means with ranges shown in parentheses (except where noted).

G6PD = glucose-6-phosphate dehydrogenase; ALT = alanine aminotransferase; BUN = blood urea nitrogen; RBC = red blood cells; MCV = mean corpuscular volume; MCHC = mean corpuscular hemoglobin concentration; WBC = white blood cells.

* Student 2-tailed t-test except where noted.
† Fisher exact test.

with an OR of 9.80 for the dichotomous variable (95% CI, 3.11–30.88).

The association of WBC count with recrudescence also was confirmed with logistic regression (OR, 1.24; 95% CI, 1.00–1.53). The OR indicates the increase in odds of recrudescence for each increase of 1,000/μL in WBC count. When controlling for parasitemia, the OR for recrudescence with increasing WBC count remained approximately the same but lost significance (OR, 1.20; 95% CI, 0.94–1.53). To explore the issue of host WBC count and recrudescent malaria, the types and amounts of WBC were determined. WBC types measured included eosinophils, basophils, monocytes, lymphocytes, and banded and segmented neutrophils. The measurements of each of these WBCs were analyzed as continuous variables to test for an association with recrudescence (trend) using logistic regression.

In univariate regression of WBC types, eosinophil, basophil, monocyte, and lymphocyte levels had no association with recrudescence (data not shown). Band neutrophils had an OR of 1.01 (95% CI, 1.00–1.02), and segmented neutrophils had an OR of 1.00 (95% CI, 1.00–1.01). When controlling for parasitemia, segmented neutrophils had an OR of 1.00 (95% CI, 1.00–1.01). The WBC types individually did not have a meaningful association with recrudescence.

We then evaluated whether time to recrudescence was associated with any particular host factor. Survival analyses were performed for all of the variables in Table 1 versus time to recrudescence. Significant associations were found for many of the same variables as in bivariate analysis (parasitemia, RBC count, hemoglobin level), which suggest that time to recrudescence depends on the parasite burden. We also found that time to recrudescence depended on blood urea nitrogen (BUN) level. Figure 2 shows survival curves of recrudescent patients categorized into normal (≤20 mg/dl) and high (>20 mg/dl) categories. The hazard ratio decreased significantly with the higher level of BUN (P = 0.028). Patients with high BUN levels (and poorer renal function) had recrudescence later than patients with low BUN levels.

**DISCUSSION**

To our knowledge, this is the first study to look at risk factors for failure by artemisinin monotherapy. The predominant risk factor for recrudescence seems to be a high parasite burden. Among patients with recrudescences, those with poorer renal function tended to have recrudescence later. There were no differences in IC50 values between strains isolated from recrudescent and nonrecrudescent patients on admission or between admission and recrudescent strains from patients having recrudescence. Few mutations were found in the *pfmdr1* gene. These data suggest that artemisinin failures were not due to drug-resistant parasites.

In this study, 31% of patients recrudesced during the 28-day observation period. Previous studies showed recrudescence rates after treatment with various regimens of artemisinin derivatives of 3–50%. Longer periods of treatment are associated with lower recrudescence rates. Combination with another drug, such as mefloquine, also reduces the appearance of recrudescence. In some instances, reported recrudescence rates may be artifactually high because reinfections might be mistaken for recrudescences. In this study, however, none of the 32 recrudescent patients were cases of reinfections because all of the patients remained in the hospital in Bangkok for 28 days, where they had no exposure to infected mosquitoes, and had recrudescence during that time.
As shown in Table 1, the parasite burdens (parasites/µl) on the day of admission of recrudescent patients were significantly higher than those of nonrecrudescent patients. Patients with parasitemias >10,000 parasites/µl of blood had 9.8 times the odds of recrudescence than patients with parasitemias <10,000 parasites/µl. These data are consistent with previous studies on quinine and mefloquine, which also showed that recrudescent patients tended to have higher parasitemias before treatment than nonrecrudescent patients. A previous study of artemisinin monotherapy also found higher recrudescence rates with higher parasitemia; however, the association was not as strong as the one reported here. Higher admission parasite burdens could predispose to recrudescence by increasing the likelihood of a parasite escaping destruction.

The range of in vitro IC₅₀ values for dihydro-artemisinin found here (0.14–2.0 ng/ml) are consistent ranges previously reported for Thai isolates (0.24–8.1 ng/ml). The data presented here indicate that recrudescence after artemisin treatment was not due to the development of parasite drug resistance. This finding is consistent with in vitro studies on recrudescence.

An association was found between high BUN level and time to recrudescence. Poor renal function may be associated with later recrudescence, perhaps because it reduces renal clearance of the drug, allowing the drug to remain at therapeutic levels in the plasma for longer periods. A longer duration of therapy may delay or prevent recrudescence; however, another study did not find longer duration of artemisin therapy to reduce recrudescence rates.

One implication of these data is the possibility of offering longer or different therapies to patients depending on their initial parasite burdens. Admission parasitemias might be useful in helping clinicians choose therapeutic regimens.

Received May 7, 2002. Accepted for publication September 30, 2002.

Acknowledgments: We are grateful to the patients for their cooperation. We thank Donglin Zeng (Department of Biostatistics, University of North Carolina School of Public Health) for statistical help. Financial support: This work was supported by grants from the U.S. National Institutes of Health (R21 AI45426 and R01 AI51320).

Authors’ addresses: Wanida Ittarat and Panthip Rattanasinganchan, Department of Clinical Microscopy, Faculty of Medical Technology, Mahidol University, Bangkok, 10700, Thailand, Telephone: 66-2-4197169, Fax: 66-2-4124110, E-mail: mtwit@mucc.mahidol.ac.th. Amy L. Pickard, Department of Epidemiology, University of North Carolina School of Public Health for statistical help.

POLRAT WILAIRATANA AND SORNCHAI LOOAREESUWAN, Department of Clinical Tropical Medicine and Bangkok Hospital for Tropical Diseases, Faculty of Tropical Medicine, Mahidol University, Bangkok, 10700, Thailand, Telephone: 66-2-4197169, Fax: 66-2-4124110, E-mail: apickard@email.unc.edu.
REFERENCES


